Supplementary Materials Supplementary information: eTables1-4 and eFigure 1 gotj044168. durations of survival without failure were 19.8 months for rituximab, 15.6 months for abatacept, and 19.1 months for tocilizumab. Average durations were greater with rituximab (LEDwf 4.1, 95% confidence interval 3.1 to 5.2) and tocilizumab (3.5, 2.1 to 5.0) than with abatacept, and uncertainty about tocilizumab… Continue reading Supplementary Materials Supplementary information: eTables1-4 and eFigure 1 gotj044168. durations of